公开(公告)号：US20220362366A1

公开(公告)日：2022-11-17

申请号：US17761457

申请日：2020-09-17

Applicant: Ohio State Innovation Foundation

Inventor： Pravin T.P. KAUMAYA

IPC: A61K39/00 ,  A61P35/00 ,  A61P37/02 ,  C07K16/28

Abstract: Disclosed are compositions related to synthetic PD-L1 peptides, chimeric PD-L1 peptides, anti-PD-L1 antibodies and N methods of treating cancers, autoimmune diseases, and Alzheimer's disease using said peptides or antibodies.

公开(公告)号：US20250059256A1

公开(公告)日：2025-02-20

申请号：US18790489

申请日：2024-07-31

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： Pravin T.P. KAUMAYA

IPC: C07K14/72 ,  A61K9/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/34 ,  A61K47/44 ,  A61K47/64 ,  A61K47/65 ,  C07K14/435 ,  C07K14/475 ,  C07K14/82 ,  C07K16/28 ,  C07K16/32 ,  C12Q1/6883

Abstract: Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.

公开(公告)号：US20190185542A1

公开(公告)日：2019-06-20

申请号：US16292032

申请日：2019-03-04

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： Pravin T.P. KAUMAYA

IPC: C07K14/72 ,  A61K47/64 ,  A61K47/34 ,  A61K47/44 ,  C07K14/82 ,  C07K14/435 ,  C07K14/475 ,  A61K39/00 ,  A61K47/65 ,  C12Q1/6883 ,  A61K9/00 ,  C07K16/28 ,  C07K16/32

Abstract: Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.

公开(公告)号：US20160002313A1

公开(公告)日：2016-01-07

申请号：US14770335

申请日：2014-02-25

Applicant: OHIO STATE INNOVATION FOUNDATION

Inventor： Pravin T.P. KAUMAYA

IPC: C07K14/72 ,  C07K14/82 ,  A61K47/48 ,  A61K39/00 ,  A61K47/34 ,  A61K47/44 ,  C07K14/435 ,  C07K14/475

CPC classification number: C07K14/72 ,  A61K9/0019 ,  A61K38/00 ,  A61K39/0005 ,  A61K39/0011 ,  A61K47/34 ,  A61K47/44 ,  A61K47/646 ,  A61K47/65 ,  A61K2039/505 ,  A61K2039/545 ,  A61K2039/5555 ,  A61K2039/55566 ,  A61K2039/585 ,  A61K2039/6075 ,  A61K2039/627 ,  A61K2039/70 ,  C07K14/435 ,  C07K14/475 ,  C07K14/721 ,  C07K14/82 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/732 ,  C12Q1/6883

Abstract: Provided herein are HER-3, HER-1 and IGF-1R B cell epitopes, peptide mimics, chimeric peptides and multivalent peptides. In some embodiments, the chimeric peptides include one or more HER-3, HER-1 and/or IGF-1R B cell epitopes, a linker, and a T helper cell (Th cell) epitope. Pharmaceutical compositions are also provided that contain one or more HER-3, HER-1 and/or IGF-1R chimeric peptides, and optionally, one or more HER-2 chimeric peptides and/or VEGF peptides. Also included herein are methods of treating a cancer using the HER-3, HER-1 and IGF-1R B cell epitopes, chimeric peptides and multivalent peptides.

Abstract translation: 本文提供了HER-3，HER-1和IGF-1R B细胞表位，肽模拟物，嵌合肽和多价肽。 在一些实施方案中，嵌合肽包括一个或多个HER-3，HER-1和/或IGF-1R B细胞表位，接头和T辅助细胞（Th细胞）表位。 还提供了含有一种或多种HER-3，HER-1和/或IGF-1R嵌合肽以及任选的一种或多种HER-2嵌合肽和/或VEGF肽的药物组合物。 本文还包括使用HER-3，HER-1和IGF-1R B细胞表位，嵌合肽和多价肽治疗癌症的方法。